ENSYSCE BIOSCIENCES, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Amount
ENSYSCE BIOSCIENCES, INC. (ENSC) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Amount of -$3.42 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-10.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges · last filed 2025-03-10
- ENSYSCE BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, restructuring charges, amount for fiscal 2024 was -$3.42K.
- ENSYSCE BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, restructuring charges, amount for fiscal 2023 was -$90.39K.
- ENSYSCE BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, restructuring charges, amount for fiscal 2022 was -$234.21K, a 114.45% decline from fiscal 2021.
- ENSYSCE BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, restructuring charges, amount for fiscal 2021 was $1.62M, a 12582.69% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Amount 12 month |
|---|---|
| 2024-12-31 | -$3.42K 10-K · filed 2025-03-10 |
| 2023-12-31 | -$90.39K 10-K · filed 2025-03-10 |
| 2022-12-31 | -$234.21K 10-K · filed 2024-03-15 |
| 2021-12-31 | $1.62M 10-K · filed 2023-03-30 |
| 2020-12-31 | $12.78K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |